Trials / Completed
CompletedNCT02975700
A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
A Phase I/II Open Label, Multicenter Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase I/II study is to evaluate safety, pharmacokinetics, and preliminary efficacy of the investigational drug PLX3397 in subjects with unresectable or metastatic KIT-mutated melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PLX3397 | 1000 mg/day (400 mg in the morning and 600 mg in the evening) |
Timeline
- Start date
- 2017-01-31
- Primary completion
- 2018-08-31
- Completion
- 2024-10-11
- First posted
- 2016-11-29
- Last updated
- 2026-01-13
- Results posted
- 2020-04-09
Locations
5 sites across 2 countries: China, South Korea
Source: ClinicalTrials.gov record NCT02975700. Inclusion in this directory is not an endorsement.